Cancer Letters
Volume 291, Issue 2 , Pages 142-149 , 28 May 2010

DNA mismatch repair and the transition to hormone independence in breast and prostate cancer

  • Lynn Martin

      Affiliations

    • Division of Radiation Therapy, School of Medicine, Trinity College Dublin, Ireland
    • Department of Haematology and Academic Unit of Clinical and Molecular Oncology, Institute of Molecular Medicine, St. James’s Hospital and Trinity College Dublin, Ireland
    • Corresponding Author InformationCorresponding author. Address: Division of Radiation Therapy and Prostate Cancer Research Group, Institute of Molecular Medicine, Trinity Centre for Health Sciences, St. James’s Hospital, Dublin 8, Ireland. Tel.: +353 1 8963253; fax: +353 1 8963246.
    • ,
  • Mary Coffey

      Affiliations

    • Division of Radiation Therapy, School of Medicine, Trinity College Dublin, Ireland
    • ,
  • Mark Lawler

      Affiliations

    • Department of Haematology and Academic Unit of Clinical and Molecular Oncology, Institute of Molecular Medicine, St. James’s Hospital and Trinity College Dublin, Ireland
    • ,
  • Donal Hollywood

      Affiliations

    • Division of Radiation Therapy, School of Medicine, Trinity College Dublin, Ireland
    • Department of Haematology and Academic Unit of Clinical and Molecular Oncology, Institute of Molecular Medicine, St. James’s Hospital and Trinity College Dublin, Ireland
    • ,
  • Laure Marignol

      Affiliations

    • Division of Radiation Therapy, School of Medicine, Trinity College Dublin, Ireland
    • Department of Haematology and Academic Unit of Clinical and Molecular Oncology, Institute of Molecular Medicine, St. James’s Hospital and Trinity College Dublin, Ireland

Received 26 May 2009 ,Revised 23 September 2009 ,Accepted 9 October 2009.

References 

  1. Hortobagyi GN, de la Garza Salazar J, Pritchard K, Amadori D, Haidinger R, Hudis CA, et al. The global breast cancer burden: variations in epidemiology and survival. Clin. Breast Cancer. 2005;6:391–401
  2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics 2009. CA Cancer J. Clin. 2009;59:225–249
  3. Henderson BE, Feigelson HS. Hormonal carcinogenesis. Carcinogenesis. 2000;21:427–433
  4. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate 1941. J. Urol. 2002;168:9–12
  5. Laufer M, Denmeade SR, Sinibaldi VJ, Carducci MA, Eisenberger MA. Complete androgen blockade for prostate cancer: what went wrong?. J. Urol. 2000;164:3–9
  6. Johnston SR. Acquired tamoxifen resistance in human breast cancer–potential mechanisms and clinical implications. Anticancer Drug. 1997;8:911–930
  7. A.M. Ferreira, H. Westers, A. Albergaria, R. Seruca, R.M. Hofstra, Estrogens, MSI and Lynch syndrome-associated tumors, Biochim. Biophys. Acta (2009).
  8. Ricke WA, Ishii K, Ricke EA, Simko J, Wang Y, Hayward SW, et al. Steroid hormones stimulate human prostate cancer progression and metastasis. Int. J. Cancer. 2006;118:2123–2131
  9. Chatterjee B. The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer. Mol. Cell Biochem. 2003;253:89–101
  10. Karan D, Schmied BM, Dave BJ, Wittel UA, Lin MF, Batra SK. Decreased androgen-responsive growth of human prostate cancer is associated with increased genetic alterations. Clin. Cancer Res. 2001;7:3472–8340
  11. Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J. Natl. Cancer Inst. 2008;100:170–183
  12. Chatterjee SK, Zetter BR. Cancer biomarkers: knowing the present and predicting the future. Future Oncol. 2005;1:37–50
  13. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat. Rev. Cancer. 2005;5:845–856
  14. Hawn MT, Umar A, Carethers JM, Marra G, Kunkel TA, Boland CR, et al. Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint. Cancer Res. 1995;55:3721–3725
  15. Gibson SL, Narayanan L, Hegan DC, Buermeyer AB, Liskay RM, Glazer PM. Overexpression of the DNA mismatch repair factor, PMS2, confers hypermutability and DNA damage tolerance. Cancer Lett. 2006;244:195–202
  16. Li GM. Mechanisms and functions of DNA mismatch repair. Cell Res. 2008;18:85–98
  17. Peltomaki P. Role of DNA mismatch repair defects in the pathogenesis of human cancer. J. Clin. Oncol. 2003;21:1174–1179
  18. Iyer RR, Pluciennik A, Burdett V, Modrich PL. DNA mismatch repair: functions and mechanisms. Chem. Rev. 2006;106:302–323
  19. Jiricny J. The multifaceted mismatch-repair system. Nat. Rev. Mol. Cell Biol. 2006;7:335–346
  20. Franchitto A, Pichierri P, Piergentili R, Crescenzi M, Bignami M, Palitti F. The mammalian mismatch repair protein MSH2 is required for correct MRE11 and RAD51 relocalization and for efficient cell cycle arrest induced by ionizing radiation in G2 phase. Oncogene. 2003;22:2110–2120
  21. Kobayashi K, Karran P, Oda S, Yanaga K. Involvement of mismatch repair in transcription-coupled nucleotide excision repair. Hum. Cell. 2005;18:103–115
  22. Davis TW, Wilson-Van Patten C, Meyers M, Kunugi KA, Cuthill S, Reznikoff C, et al. Defective expression of the DNA mismatch repair protein, MLH1, alters G2-M cell cycle checkpoint arrest following ionizing radiation. Cancer Res. 1998;58:767–778
  23. Cejka P, Stojic L, Mojas N, Russell AM, Heinimann K, Cannavo E, et al. Methylation-induced G(2)/M arrest requires a full complement of the mismatch repair protein hMLH1. Embo. J. 2003;22:2245–2254
  24. Hirose Y, Katayama M, Stokoe D, Haas-Kogan DA, Berger MS, Pieper RO. The p38 mitogen-activated protein kinase pathway links the DNA mismatch repair system to the G2 checkpoint and to resistance to chemotherapeutic DNA-methylating agents. Mol. Cell Biol. 2003;23:8306–8315
  25. Yeh CC, Lee C, Dahiya R. DNA mismatch repair enzyme activity and gene expression in prostate cancer. Biochem. Biophys. Res. Commun. 2001;285:409–413
  26. Mohd AB, Palama B, Nelson SE, Tomer G, Nguyen M, Huo X, et al. Truncation of the C-terminus of human MLH1 blocks intracellular stabilization of PMS2 and disrupts DNA mismatch repair. DNA Repair (Amst). 2006;5:347–361
  27. Chintamani , Jha BP, Bhandari V, Bansal A, Saxena S, Bhatnagar D. The expression of mismatched repair genes and their correlation with clinicopathological parameters and response to neo-adjuvant chemotherapy in breast cancer. Int. Semin. Surg. Oncol. 2007;4:5
  28. Koster F, Schroer A, Fischer D, Horn AK, Diedrich K, Friedrich M. Immunohistochemistry of proteins for DNA mismatch repair in correlation to prognostic factors of mammarian cancer. Oncol. Rep. 2007;17:1223–1227
  29. Jenkins MA, Baglietto L, Dowty JG, Van Vliet CM, Smith L, Mead LJ, et al. Cancer risks for mismatch repair gene mutation carriers: a population-based early onset case-family study. Clin. Gastroenterol. Hepatol. 2006;4:489–498
  30. Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the international collaborative group on HNPCC. Gastroenterology. 1999;116:1453–1456
  31. Schafmayer C, Buch S, Egberts JH, Franke A, Brosch M, El Sharawy A, et al. Genetic investigation of DNA-repair pathway genes PMS2, MLH1, MSH2, MSH6, MUTYH, OGG1 and MTH1 in sporadic colon cancer. Int. J. Cancer. 2007;121:555–558
  32. Takano K, Ichikawa Y, Ueno E, Ohwada M, Suzuki M, Tsunoda H, et al. Microsatellite instability and expression of mismatch repair genes in sporadic endometrial cancer coexisting with colorectal or breast cancer. Oncol. Rep. 2005;13:11–16
  33. Bianchi F, Rosati S, Belvederesi L, Loretelli C, Catalani R, Mandolesi A, et al. MSH2 splice site mutation and endometrial cancer. Int. J. Gynecol. Cancer. 2006;16:1419–1423
  34. Kanemitsu K, Kawasaki K, Nakamura M, Li D, Yasuda T, Kuroda D, et al. MSI is frequently recognized among gastric cancer patients with a family history of cancer. Hepatogastroenterology. 2007;54:2410–2414
  35. Yamamoto M, Taguchi K, Baba H, Endo K, Kohnoe S, Okamura T, et al. Loss of protein expression of hMLH1 and hMSH2 with double primary carcinomas of the stomach and colorectum. Oncol. Rep. 2006;16:41–47
  36. Nunn J, Nagini S, Risk JM, Prime W, Maloney P, Liloglou T, et al. Allelic imbalance at the DNA mismatch repair loci, hMSH2, hMLH1, hPMS1, hPMS2 and hMSH3 in squamous cell carcinoma of the head and neck. Oral Oncol. 2003;39:115–129
  37. Nijhuis ER, Nijman HW, Oien KA, Bell A, Ten Hoor KA, Reesink-Peters N, et al. Loss of MSH2 protein expression is a risk factor in early stage cervical cancer. J. Clin. Pathol. 2007;60:824–830
  38. Chen Y, Wang J, Fraig MM, Henderson K, Bissada NK, Watson DK, et al. Alterations in PMS2, MSH2 and MLH1 expression in human prostate cancer. Int. J. Oncol. 2003;22:1033–1043
  39. Murata H, Khattar NH, Gu L, Li GM. Roles of mismatch repair proteins hMSH2 and hMLH1 in the development of sporadic breast cancer. Cancer Lett. 2005;223:143–150
  40. Wheeler JM, Bodmer WF, Mortensen NJ. DNA mismatch repair genes and colorectal cancer. Gut. 2000;47:148–153
  41. Siah SP, Quinn DM, Bennett GD, Casey G, Flower RL, Suthers G, et al. Microsatellite instability markers in breast cancer: a review and study showing MSI was not detected at ‘BAT 25’ and ‘BAT 26’ microsatellite markers in early-onset breast cancer. Breast Cancer Res. Treat. 2000;60:135–142
  42. Caldes T, Perez-Segura P, Tosar A, De La Hoya M, Diaz-Rubio E. Low frequency of microsatellite instability in sporadic breast cancer. Int. J. Oncol. 2000;16:1235–1242
  43. Anbazhagan R, Fujii H, Gabrielson E. Microsatellite instability is uncommon in breast cancer. Clin. Cancer Res. 1999;5:839–844
  44. Lee SC, Berg KD, Sherman ME, Griffin CA, Eshleman JR. Microsatellite instability is infrequent in medullary breast cancer. Am. J. Clin. Pathol. 2001;115:823–827
  45. Imyanitov EN, Togo AV, Suspitsin EN, Grigoriev MY, Pozharisski KM, Turkevich EA, et al. Evidence for microsatellite instability in bilateral breast carcinomas. Cancer Lett. 2000;154:9–17
  46. Toyama T, Iwase H, Iwata H, Hara Y, Omoto Y, Suchi M, et al. Microsatellite instability in in situ and invasive sporadic breast cancers of Japanese women. Cancer Lett. 1996;108:205–209
  47. Rosenberg CL, Larson PS, Romo JD, De Las Morenas A, Faller DV. Microsatellite alterations indicating monoclonality in atypical hyperplasias associated with breast cancer. Hum. Pathol. 1997;28:214–219
  48. Huang Y, Bove B, Wu Y, Russo IH, Yang X, Zekri A, et al. Microsatellite instability during the immortalization and transformation of human breast epithelial cells in vitro. Mol. Carcinogen. 1999;24:118–127
  49. Shen KL, Yang LS, Hsieh HF, Chen CJ, Yu JC, Tsai NM, et al. Microsatellite alterations on human chromosome 11 in in situ and invasive breast cancer: a microdissection microsatellite analysis and correlation with p53, ER (estrogen receptor) and PR (progesterone receptor) protein immunoreactivity. J. Surg. Oncol. 2000;74:100–107
  50. Ellsworth RE, Ellsworth DL, Love B, Patney HL, Hoffman LR, Kane J, et al. Correlation of levels and patterns of genomic instability with histological grading of DCIS. Ann. Surg. Oncol. 2007;14:3070–3077
  51. Azzouzi AR, Catto JW, Rehman I, Larre S, Roupret M, Feeley KM, et al. Clinically localised prostate cancer is microsatellite stable. BJU Int. 2007;99:1031–1035
  52. Dahiya R, Lee C, McCarville J, Hu W, Kaur G, Deng G. High frequency of genetic instability of microsatellites in human prostatic adenocarcinoma. Int. J. Cancer. 1997;72:762–767
  53. Perinchery G, Nojima D, Goharderakhshan R, Tanaka Y, Alonzo J, Dahiya R. Microsatellite instability of dinucleotide tandem repeat sequences is higher than trinucleotide, tetranucleotide and pentanucleotide repeat sequences in prostate cancer. Int. J. Oncol. 2000;16:1203–1209
  54. Watanabe M, Imai H, Kato H, Shiraishi T, Ushijima T, Nagao M, et al. Microsatellite instability in latent prostate cancers. Int. J. Cancer. 1996;69:394–397
  55. Ahman AK, Jonsson BA, Damber JE, Bergh A, Gronberg H. Low frequency of microsatellite instability in hereditary prostate cancer. BJU Int. 2001;87:334–338
  56. Velasco A, Hewitt SM, Albert PS, Hossein M, Rosenberg H, Martinez C, et al. Differential expression of the mismatch repair gene hMSH2 in malignant prostate tissue is associated with cancer recurrence. Cancer. 2002;94:690–699
  57. Brennetot C, Buhard O, Jourdan F, Flejou JF, Duval A, Hamelin R. Mononucleotide repeats BAT-26 and BAT-25 accurately detect MSI-H tumors and predict tumor content: implications for population screening. Int. J. Cancer. 2005;113:446–450
  58. Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: part I. The utility of immunohistochemistry. J. Mol. Diagn. 2008;10:293–300
  59. Baudhuin LM, Burgart LJ, Leontovich O, Thibodeau SN. Use of microsatellite instability and immunohistochemistry testing for the identification of individuals at risk for Lynch syndrome. Fam. Cancer. 2005;4:255–265
  60. Shia J, Klimstra DS, Nafa K, Offit K, Guillem JG, Markowitz AJ, et al. Value of immunohistochemical detection of DNA mismatch repair proteins in predicting germline mutation in hereditary colorectal neoplasms. Am. J. Surg. Pathol. 2005;29:96–104
  61. Lindor NM, Petersen GM, Hadley DW, Kinney AY, Miesfeldt S, Lu KH, et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA. 2006;296:1507–1517
  62. Zhang L. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: part II. The utility of microsatellite instability testing. J. Mol. Diagn. 2008;10:301–307
  63. Naqvi RA, Hussain A, Deo SS, Kukreti H, Chauhan M, Sarin R, et al. Hypermethylation analysis of mismatch repair genes (hmlh1 and hmsh2) in locally advanced breast cancers in Indian women. Hum. Pathol. 2008;39:672–680
  64. Smith TR, Levine EA, Freimanis RI, Akman SA, Allen GO, Hoang KN, et al. Polygenic model of DNA repair genetic polymorphisms in human breast cancer risk. Carcinogenesis. 2008;29:2132–2138
  65. Chen Y, Wang J, Fraig MM, Metcalf J, Turner WR, Bissada NK, et al. Defects of DNA mismatch repair in human prostate cancer. Cancer Res. 2001;61:4112–4121
  66. Burger M, Denzinger S, Hammerschmied CG, Tannapfel A, Obermann EC, Wieland WF, et al. Elevated microsatellite alterations at selected tetranucleotides (EMAST) and mismatch repair gene expression in prostate cancer. J. Mol. Med. 2006;84:833–841
  67. Strom SS, Spitz MR, Yamamura Y, Babaian RJ, Scardino PT, Wei Q. Reduced expression of hMSH2 and hMLH1 and risk of prostate cancer: a case-control study. Prostate. 2001;47:269–275
  68. Chuang ST, Adley B, Han M, Lin F, Yang XJ, Catalona WJ. Mutant L Homologue 1 (MLH1): a possible new immunohistochemical marker for prostatic cancer. Histopathology. 2008;52:247–2450
  69. Murata H, Khattar NH, Kang Y, Gu L, Li GM. Genetic and epigenetic modification of mismatch repair genes hMSH2 and hMLH1 in sporadic breast cancer with microsatellite instability. Oncogene. 2002;21:5696–5703
  70. Ollikainen M, Hannelius U, Lindgren CM, Abdel-Rahman WM, Kere J, Peltomaki P. Mechanisms of inactivation of MLH1 in hereditary nonpolyposis colorectal carcinoma: a novel approach. Oncogene. 2007;26:4541–4549
  71. Raptis S, Mrkonjic M, Green RC, Pethe VV, Monga N, Chan YM, et al. MLH1-93G>A promoter polymorphism and the risk of microsatellite-unstable colorectal cancer. J. Natl. Cancer Inst. 2007;99:463–474
  72. Leach FS, Velasco A, Hsieh JT, Sagalowsky AI, McConnell JD. The mismatch repair gene hMSH2 is mutated in the prostate cancer cell line LNCaP. J. Urol. 2000;164:1830–1833
  73. Martin L, Marples B, Coffey M, Lawler M, Hollywood D, Marignol L. Recognition of O6MeG lesions by MGMT and mismatch repair proficiency may be a prerequisite for low-dose radiation hypersensitivity. Radiat. Res. 2009;172:405–413
  74. Prtilo A, Leach FS, Markwalder R, Kappeler A, Burkhard FC, Cecchini MG, et al. Tissue microarray analysis of hMSH2 expression predicts outcome in men with prostate cancer. J. Urol. 2005;174:1814–1818(discussion 1818)
  75. Son BH, Ahn SH, Ko CD, Ka IW, Gong GY, Kim JC. Significance of mismatch repair protein expression in the chemotherapeutic response of sporadic invasive ductal carcinoma of the breast. Breast J. 2004;10:20–26
  76. Casorelli I, Russo MT, Bignami M. Role of mismatch repair and MGMT in response to anticancer therapies. Anticancer Agent Med. Chem. 2008;8:368–380
  77. Bellacosa A. Functional interactions and signaling properties of mammalian DNA mismatch repair proteins. Cell Death Differ. 2001;8:1076–1092
  78. Benachenhou N, Guiral S, Gorska-Flipot I, Labuda D, Sinnett D. Frequent loss of heterozygosity at the DNA mismatch-repair loci hMLH1 and hMSH3 in sporadic breast cancer. Br. J. Cancer. 1999;79:1012–1017
  79. Hirata H, Hinoda Y, Kawamoto K, Kikuno N, Suehiro Y, Okayama N, et al. Mismatch repair gene MSH3 polymorphism is associated with the risk of sporadic prostate cancer. J. Urol. 2008;179:2020–2024
  80. Balogh GA, Russo IH, Russo J. Truncation of the mismatch repair protein PMS2 during the neoplastic transformation of human breast epithelial cells in vitro. Int. J. Oncol. 2004;25:381–387
  81. Norris AM, Woodruff RD, D’Agostino RB, Clodfelter JE, Scarpinato KD. Elevated levels of the mismatch repair protein PMS2 are associated with prostate cancer. Prostate. 2007;67:214–225
  82. Marra G, Chang CL, Laghi LA, Chauhan DP, Young D, Boland CR. Expression of human MutS homolog 2 (hMSH2) protein in resting and proliferating cells. Oncogene. 1996;13:2189–2196
  83. Miyamoto T, Shiozawa T, Kashima H, Feng YZ, Suzuki A, Kurai M, et al. Estrogen up-regulates mismatch repair activity in normal and malignant endometrial glandular cells. Endocrinology. 2006;147:4863–4870
  84. Wada-Hiraike O, Yano T, Nei T, Matsumoto Y, Nagasaka K, Takizawa S, et al. The DNA mismatch repair gene hMSH2 is a potent coactivator of oestrogen receptor alpha. Br. J. Cancer. 2005;92:2286–2291
  85. Norris AM, Gentry M, Peehl DM, D’Agostino R, Scarpinato KD. The elevated expression of a mismatch repair protein is a predictor for biochemical recurrence after radical prostatectomy. Cancer Epidemiol. Biomarkers. Prev. 2009;18:57–64
  86. Karihtala P, Winqvist R, Syvaoja JE, Kinnula VL, Soini Y. Increasing oxidative damage and loss of mismatch repair enzymes during breast carcinogenesis. Eur. J. Cancer. 2006;42:2653–2659
  87. Bock N, Meden H, Regenbrecht M, Junemann B, Wangerin J, Marx D. Expression of the mismatch repair protein hMSH2 in carcinoma in situ and invasive cancer of the breast. Anticancer Res. 2000;20:119–124
  88. Fromont G, Chene L, Vidaud M, Vallancien G, Mangin P, Fournier G, et al. Differential expression of 37 selected genes in hormone-refractory prostate cancer using quantitative taqman real-time RT-PCR. Int. J. Cancer. 2005;114:174–181
  89. Caldes T, Perez-Segura P, Tosar A, de La Hoya M, Diaz-Rubio E. Microsatellite instability correlates with negative expression of estrogen and progesterone receptors in sporadic breast cancer. Teratogen. Carcinogen. Mutagen. 2000;20:283–291
  90. Shaw JA, Walsh T, Chappell SA, Carey N, Johnson K, Walker RA. Microsatellite instability in early sporadic breast cancer. Br. J. Cancer. 1996;73:1393–1397
  91. Velasco A, Albert PS, Rosenberg H, Martinez C, Leach FS. Clinicopathologic implications of hMSH2 gene expression and microsatellite instability in prostate cancer. Cancer Biol. Ther. 2002;1:362–367
  92. Balogh GA, Heulings RC, Russo J. The mismatch repair gene hPMS2 is mutated in primary breast cancer. Int. J. Mol. Med. 2006;18:853–857
  93. Khilko N, Bourne P, Qi Y, Ping T. Mismatch repair genes hMLH1 and hMSH2 may not play an essential role in breast carcinogenesis. Int. J. Surg. Pathol. 2007;15:233–241
  94. Wong EM, Tesoriero AA, Pupo GM, McCredie MR, Giles GG, Hopper JL, et al. Is MSH2 a breast cancer susceptibility gene?. Fam. Cancer. 2008;7:151–155

PII: S0304-3835(09)00629-6

doi: 10.1016/j.canlet.2009.10.007

Cancer Letters
Volume 291, Issue 2 , Pages 142-149 , 28 May 2010

Article Tools

* Image Usage & Resolution